Generic Medicine Info
Indications and Dosage
Acute musculoskeletal disorders, Osteoarthritis, Rheumatoid arthritis
Adult: 20 mg as a single dose, taken at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest possible duration.

Acute musculoskeletal disorders, Osteoarthritis, Rheumatoid arthritis
Adult: Initially, 20 mg IM/IV as a single dose given for 1-2 days, to be continued w/ the oral form, administered at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest duration.
Should be taken with food. Take w/ or immediately after meals.
Dissolve lyophilisate in 2 mL of sterile water for inj.
Hypersensitivity to tenoxicam, aspirin or other NSAIDs. History of or active peptic ulceration, GI bleeding (melaena, haematemesis) or severe gastritis; severe heart failure. Last trimester of pregnancy.
Special Precautions
Patient w/ history of or active bronchial asthma, uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, risk factors for CV disease (e.g. HTN, hyperlipidaemia, DM, smoking), history of GI disease, fluid retention and oedema. Patient who will undergo major surgery (e.g. joint replacement). Elderly. Renal and hepatic impairment.
Adverse Reactions
Dyspepsia, nausea, abdominal pain and discomfort, constipation, diarrhoea, flatulence, indigestion, epigastric distress, stomatitits, anorexia; peripheral oedema; headache, dizziness; allergic reactions, asthma, bronchospasm, dyspnoea, rash, pruritus; decreased Hb, anaemia, thrombocytopenia, non-thrombocytopenic purpura, leucopenia, eosinophilia, epistaxis; increased serum transaminase levels; swollen eyes, blurred vision, eye irritation, malaise, tinnitus; oedema, HTN, cardiac failure.
Potentially Fatal: Peptic ulceration, GI bleeding, anaphylaxis, Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, nephrotoxicity, arterial thrombotic events (e.g. MI or stroke), hepatitis, jaundice.
Parenteral/PO: Z (NSAIDs caused foetal ductus arteriosus premature closure, foetal renal impairment and persistent pulmonary hypertension. Avoid near term, else use lowest dose for shortest time.)
Monitoring Parameters
Monitor renal, hepatic and cardiac functions.
Symptoms: Headache, nausea, vomiting, epigastric pain, GI bleeding, rarely diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, fainting, occasionally convulsions. Acute renal failure and liver damage may occur. Management: Symptomatic treatment. Ensure good urine output. Frequent or prolonged convulsions should be treated w/ IV diazepam. May administer an H2-antagonist.
Drug Interactions
Increased risk of adverse effects (particularly GI) w/ salicylates and other NSAIDs. May enhance the anticoagulant effect of warfarin and other anticoagulants. May reduce the effect of antihypertensive drugs. Increased risk of nephrotoxicity w/ ciclosporin. Increased risk of convulsions w/ quinolones. May decrease the elimination of lithium. May interfere w/ the natriuretic action of diuretics. May enhance the toxicity of methotrexate. May reduce the effects of mifepristone. Increased risk of GI bleeding w/ corticosteroids.
Food Interaction
Food may delay the rate of absorption.
Description: Tenoxicam is an NSAID which has marked anti-inflammatory and analgesic activity and some antipyretic activity. As w/ other NSAIDs, the precise mode of action is unknown, though it is probably multifactorial, involving inhibition of prostaglandin biosynthesis and reduction of leucocyte accumulation at the inflammatory site.
Absorption: Well absorbed from the GI tract. Rapidly absorbed after IM inj. Food may delay the rate (to approx 6 hr) of absorption. Time to peak plasma concentration: Approx 2 hr.
Distribution: Penetrates synovial fluid. Plasma protein binding: Approx 99%.
Metabolism: Completely metabolised to inactive metabolites.
Excretion: Mainly via urine, some via bile as glucoronide conjugates of the metabolites. Plasma elimination half-life: 42-81 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tenoxicam, CID=54677971, https://pubchem.ncbi.nlm.nih.gov/compound/Tenoxicam (accessed on Jan. 23, 2020)

Store below 30°C.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Anon. Tenoxicam. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/11/2014.

Buckingham R (ed). Tenoxicam. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/11/204.

Tenoxicam 20 mg Lyophilisate for Solution for Injection (Chemidex Pharma Ltd). MHRA. https://products.mhra.gov.uk/. Accessed 21/11/2014.

Disclaimer: This information is independently developed by MIMS based on Tenoxicam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in